Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer
This study has been completed.
Information provided by (Responsible Party):
First received: March 18, 2005
Last updated: September 24, 2015
Last verified: May 2015
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||May 2010|
|Primary Completion Date:||September 2007 (Final data collection date for primary outcome measure)|
Kaufman B, Trudeau M, Awada A, Blackwell K, Bachelot T, Salazar V, DeSilvio M, Westlund R, Zaks T, Spector N, Johnston S. Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. Lancet Oncol. 2009 Jun;10(6):581-8. doi: 10.1016/S1470-2045(09)70087-7.